Saturday, July 11, 2026

pharma · Alopecia areata · Multiple myeloma

First Biotech (Australia)

Pfizer Australia Pty is a pharma organization headquartered in AU. Primary therapeutic focus areas include Alopecia areata, Multiple myeloma, Heart failure, Acute Migraine (with or without aura), Transthyretin amyloidosi

Norwest House, 710 Collins Street, Melbourne, VIC 3008, AU HQ
2017 Founded
2 Employees
TGA registrant Type
Company details
Status
Public
HQ
Norwest House, 710 Collins Street, Melbourne, VIC 3008, AU
Founded
2017
Employees
2
Programs
126
Drugs
208
Patents
0
Clinical program

A8081075

Approved · small molecule · This Master Protocol for Crizotinib Continuation Sub-Studies has been designed to provide continued treatment access for eligible participants who continue to derive clinical benefit from study intervention in a Pfizer sponsored crizotinib parent study that will be closed

A8081075 for This Master Protocol for Crizotinib Continuation Sub-Studies has been designed to provide continued treatment access for eligible participants who continue to derive clinical benefit from study intervention in a Pfizer sponsored crizotinib parent study that will be closed is a Approved program (small_molecule) at Pfizer Australia Pty Ltd with 1 ClinicalTrials.gov record(s).

← All Pfizer Australia Pty Ltd projects Approved small molecule active

Internal code A8081075

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Pfizer Australia Pty Ltd
Phase
Approved
Modality
small_molecule
Indication
This Master Protocol for Crizotinib Continuation Sub-Studies has been designed to provide continued treatment access for eligible participants who continue to derive clinical benefit from study intervention in a Pfizer sponsored crizotinib parent study that will be closed
Status
active
Trials
1